Ngoc Nguyen, MD
Ophthalmology · San Jose, CANPI 1609935113
Payments from drug & device makers
Across 294 payments — averaging $422.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$118K
- AbbVie$1K
- Novartis$830
- Bausch & Lomb Americas Inc.$801
- Alcon$789
- Carl Zeiss Meditec USA, Inc.$360
- plus $2K from 18 others
What the payments were for
- Food & beverage$5,40694%
- Other$3606%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 2 | $118,406 |
| AbbVie(2 entities) | 88 | $1,183 |
| Novartis | 45 | $830 |
| Bausch & Lomb Americas Inc. | 33 | $801 |
| Alcon | 25 | $789 |
| Carl Zeiss Meditec USA, Inc. | 1 | $360 |
| Oyster Point Pharma, Inc. | 19 | $351 |
| Sun Pharmaceutical Industries Inc. | 20 | $266 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $201 |
| Amgen(2 entities) | 7 | $173 |
| Thea Pharma Inc. | 7 | $151 |
| Akorn Operating Company LLC | 5 | $98 |
| ANI Pharmaceuticals, Inc. | 3 | $70 |
| Eyevance Pharmaceuticals LLC | 4 | $69 |
| Sight Sciences, Inc. | 4 | $67 |
| Mallinckrodt Hospital Products Inc. | 4 | $61 |
| Ivantis, Inc | 3 | $60 |
| Aerie Pharmaceuticals, Inc. | 3 | $58 |
| Glaukos Corporation | 3 | $51 |
| Kala Pharmaceuticals, Inc. | 2 | $41 |
| Akorn, Inc. | 2 | $34 |
| Sanofi Pasteur Inc. | 2 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMERA 700$360
- Rhopressa$125
- Rocklatan$125
- VYZULTA$125
- TRYPTYR$123
How this compares
$124,173 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 1,094 | $1,048,265 |
| XiidraLifitegrast | 810 | $926,420 |
| LumiganBimatoprost | 1,616 | $631,114 |
| RhopressaNetarsudil Mesylate | 1,178 | $567,334 |
| VyzultaLatanoprostene Bunod | 1,155 | $431,666 |
| Cyclosporine | 438 | $234,781 |
| TyrvayaVarenicline Tartrate | 192 | $204,810 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 665 | $182,369 |
| RocklatanNetarsudil Mesylat/Latanoprost | 333 | $173,587 |
| Brinzolamide | 667 | $161,656 |
| Alphagan PBrimonidine Tartrate | 403 | $151,117 |
| AzoptBrinzolamide | 256 | $146,614 |
| Brimonidine Tartrate | 829 | $114,461 |
| Methazolamide | 280 | $75,788 |
| ZerviateCetirizine Hcl | 136 | $72,697 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $1,183 | $1,853,4503,184 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $801 | $1,367,6101,976 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $58 | $740,9211,511 claims |
| AlconSimbrinza, Azopt | $789 | $328,983921 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $351 | $204,810192 claims |
| Eyevance Pharmaceuticals LLCZerviate | $69 | $72,697136 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $266 | $68,24289 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $201 | $43,581126 claims |
| Akorn, Inc.Zioptan | $34 | $17,01331 claims |
| Thea Pharma Inc.Iyuzeh | $151 | $11,26935 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in San Jose
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.